Robert W. Brueggemeier

4.9k total citations
122 papers, 4.0k citations indexed

About

Robert W. Brueggemeier is a scholar working on Genetics, Molecular Biology and Pharmacology. According to data from OpenAlex, Robert W. Brueggemeier has authored 122 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Genetics, 55 papers in Molecular Biology and 29 papers in Pharmacology. Recurrent topics in Robert W. Brueggemeier's work include Estrogen and related hormone effects (72 papers), Inflammatory mediators and NSAID effects (24 papers) and Bioactive Compounds and Antitumor Agents (17 papers). Robert W. Brueggemeier is often cited by papers focused on Estrogen and related hormone effects (72 papers), Inflammatory mediators and NSAID effects (24 papers) and Bioactive Compounds and Antitumor Agents (17 papers). Robert W. Brueggemeier collaborates with scholars based in United States, China and Israel. Robert W. Brueggemeier's co-authors include Edgar S. Díaz‐Cruz, John C. Hackett, Bin Su, Charles L. Shapiro, Abhijit Bhat, Y. Sugimoto, Pui‐Kai Li, Marcy J. Balunas, A. Douglas Kinghorn and Catherine E. Snider and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Robert W. Brueggemeier

121 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert W. Brueggemeier United States	34	1.9k	1.6k	858	695	630	122	4.0k
Atul Purohit United Kingdom	41	2.6k 1.3×	2.4k 1.5×	344 0.4×	1.4k 2.1×	549 0.9×	102	4.7k
Vincenzo Pezzi Italy	45	1.9k 1.0×	2.2k 1.3×	319 0.4×	621 0.9×	669 1.1×	124	5.8k
Denis Riendeau Canada	43	1.0k 0.5×	2.0k 1.2×	3.0k 3.5×	1.6k 2.3×	477 0.8×	112	6.1k
Debashis Ghosh United States	37	1.5k 0.8×	2.9k 1.8×	264 0.3×	543 0.8×	315 0.5×	88	5.2k
Jill C. Pelling United States	39	721 0.4×	2.9k 1.8×	677 0.8×	226 0.3×	931 1.5×	80	4.6k
Tea Lanišnik Rižner Slovenia	39	1.1k 0.6×	1.7k 1.0×	326 0.4×	393 0.6×	339 0.5×	166	4.6k
Joanna E. Burdette United States	36	538 0.3×	2.2k 1.4×	520 0.6×	299 0.4×	550 0.9×	182	4.8k
Elliott Sigal United States	27	497 0.3×	1.6k 1.0×	1.0k 1.2×	666 1.0×	218 0.3×	54	4.8k
Scott W. Rowlinson United States	30	536 0.3×	1.3k 0.8×	1.6k 1.9×	742 1.1×	329 0.5×	55	3.7k
Yongkui Jing China	41	437 0.2×	4.2k 2.5×	659 0.8×	790 1.1×	572 0.9×	140	5.7k

Countries citing papers authored by Robert W. Brueggemeier

Since Specialization

Citations

This map shows the geographic impact of Robert W. Brueggemeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Brueggemeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Brueggemeier more than expected).

Fields of papers citing papers by Robert W. Brueggemeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Brueggemeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Brueggemeier. The network helps show where Robert W. Brueggemeier may publish in the future.

Co-authorship network of co-authors of Robert W. Brueggemeier

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Brueggemeier. A scholar is included among the top collaborators of Robert W. Brueggemeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Brueggemeier. Robert W. Brueggemeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eloy, Josimar O., et al.. (2016). Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry. 17(1). 48–56. 25 indexed citations

Brueggemeier, Robert W.. (2015). Analogs and Antagonists of Male Sex Hormones. 1. 308–380. 3 indexed citations

Mehta, Meghna, Megan R. Lerner, Daniel J. Brackett, et al.. (2015). Oncolytic potential of a novel KGFR tyrosine kinase inhibitor using a KGFR-selective breast cancer xenograft model.. PubMed. 35(1). 47–52. 2 indexed citations

Lustberg, Maryam B., Stephen P. Povoski, Weiqiang Zhao, et al.. (2011). Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer. 11(4). 221–227. 21 indexed citations

Brueggemeier, Robert W., Alice M. Clark, Sudip Das, et al.. (2011). The Path Forward: The Future of Graduate Education in the Pharmaceutical Sciences: The Report of the 2010-2011 Research and Graduate Affairs Committee. American Journal of Pharmaceutical Education. 75(10). S13–S13. 10 indexed citations

Balunas, Marcy J., et al.. (2008). Natural Products as Aromatase Inhibitors. Anti-Cancer Agents in Medicinal Chemistry. 8(6). 646–682. 6 indexed citations

Hackett, John C., Zili Xiao, Xiaoping Zang, et al.. (2008). Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer.. PubMed. 27(6B). 3801–6. 10 indexed citations

Su, Bin, Edgar S. Díaz‐Cruz, Serena Landini, & Robert W. Brueggemeier. (2007). Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 73(1). 104–111. 22 indexed citations

Tseng, Ping‐Hui, Yu-Chieh Wang, Jing‐Ru Weng, et al.. (2006). Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. Molecular Pharmacology. 70(5). 1534–1541. 63 indexed citations

10.

Su, Bin, John C. Hackett, Edgar S. Díaz‐Cruz, Young Woo Kim, & Robert W. Brueggemeier. (2005). Lead optimization of 7-benzyloxy 2-(4′-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorganic & Medicinal Chemistry. 13(23). 6571–6577. 18 indexed citations

11.

Brueggemeier, Robert W., Edgar S. Díaz‐Cruz, Pui‐Kai Li, et al.. (2005). Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 95(1-5). 129–136. 47 indexed citations

12.

Mobley, James A. & Robert W. Brueggemeier. (2002). Increasing the DNA Damage Threshold in Breast Cancer Cells. Toxicology and Applied Pharmacology. 180(3). 219–226. 23 indexed citations

13.

Brueggemeier, Robert W., et al.. (2002). Increased proteasome‐dependent degradation of estrogen receptor‐alpha by TGF‐β1 in breast cancer cell lines. Journal of Cellular Biochemistry. 88(1). 181–190. 23 indexed citations

14.

Kim, Young‐Woo & Robert W. Brueggemeier. (2002). A convenient one-pot synthesis of 2-(alkylthio)isoflavones from deoxybenzoins using a phase transfer catalyst. Tetrahedron Letters. 43(35). 6113–6115. 17 indexed citations

15.

Brueggemeier, Robert W., Abhijit Bhat, Carl J. Lovely, et al.. (2001). 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. The Journal of Steroid Biochemistry and Molecular Biology. 78(2). 145–156. 54 indexed citations

16.

Brueggemeier, Robert W., et al.. (2001). Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. The Journal of Steroid Biochemistry and Molecular Biology. 79(1-5). 75–84. 65 indexed citations

17.

Canatan, Halit, et al.. (1997). Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells. Endocrine Research. 23(4). 311–323. 3 indexed citations

18.

Li, Pui‐Kai & Robert W. Brueggemeier. (1990). 7-Substituted Steroidal Aromatase Inhibitors: Structure-Activity Relationships and Molecular Modeling. Journal of enzyme inhibition. 4(2). 113–120. 7 indexed citations

19.

Brueggemeier, Robert W., et al.. (1989). Catechol estrogen formation in MCF-7 cell culture and effects of bromoestrogen inhibitors. Molecular and Cellular Endocrinology. 64(2). 161–167. 13 indexed citations

20.

Brueggemeier, Robert W., Eugenia Floyd, & Raymond E. Counsell. (1978). Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis. Journal of Medicinal Chemistry. 21(10). 1007–1011. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact